

For immediate release

15 October 2025

**CVS Group plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")**

Response to CMA provisional decision announcement

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its provisional decision in the veterinary market investigation. The CMA is expected to publish its full provisional decision later today.

CVS welcomes the additional certainty that this morning's announcement brings. We will be responding to the provisional decision and proposed remedies package in writing in due course and have a further hearing with the CMA in December 2025. We look forward to the publication of the final decision in March 2026 and conclusion of this market investigation promptly thereafter.

We are pleased to see that the CMA has considered our and the veterinary profession's feedback on the initial 28 remedies proposed in May 2025, which have been refined to 21 with no new remedies introduced. Whilst we do not believe that all of these remedies are fully justified, we will be working with the CMA to refine the remedies package to ensure it is workable and deliverable and have plans in place to implement them, including joint branding of our practices and the publishing of standardised price lists.

As such, the Board continues to expect the Group to trade in line with market expectations.

Contacts

CVS Group plc

Richard Fairman, Chief Executive Officer
Robin Alfonso, Chief Financial Officer
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations

via Camarco

Peel Hunt LLP (Nominated Adviser & Joint Broker)

Christopher Golden / James Steel / Andrew Clark

+44 (0)20 7418 8900

Berenberg (Joint Broker)

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

+44 (0)20 3207 7800

Camarco (Financial PR)

Ginny Pulbrook
Letaba Rimell
Tilly Butcher

cvsq@camarco.co.uk

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RSPFFLSMIEISDS